{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:12:40Z","timestamp":1772759560993,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T00:00:00Z","timestamp":1337212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00702-012-0818-7","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T15:15:55Z","timestamp":1337181355000},"page":"31-36","source":"Crossref","is-referenced-by-count":12,"title":["The effect of piribedil on l-DOPA-induced dyskinesias in a rat model of Parkinson\u2019s disease: differential role of \u03b12 adrenergic mechanisms"],"prefix":"10.1007","volume":"120","author":[{"given":"Manfred","family":"Gerlach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Halley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Riederer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"van den Buuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,17]]},"reference":[{"key":"818_CR1","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1038\/sj.npp.1301580","volume":"33","author":"ME Bardgett","year":"2008","unstructured":"Bardgett ME, Points M, Ramsey-Faulkner C, Topmiller J, Roflow J, McDaniel T, Lamontagne T, Griffith MS (2008) The effects of clonidine on discrete-trial delayed spatial alternation in two rat models of memory loss. Neuropsychopharmacology 33:1980\u20131991","journal-title":"Neuropsychopharmacology"},{"key":"818_CR2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00702-004-0251-7","volume":"112","author":"JM Brotchie","year":"2005","unstructured":"Brotchie JM, Lee J, Venderova K (2005) Levodopa-induced dyskinesia in Parkinson\u2019s disease. J Neural Transm 112:359\u2013391","journal-title":"J Neural Transm"},{"key":"818_CR3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0014-4886(86)90301-8","volume":"92","author":"RJ Carey","year":"1986","unstructured":"Carey RJ (1986) Relationship of changes in spontaneous motor activity to spontaneous circling in rats with unilateral 6-hydroxydopamine lesions of the substantia nigra. Exp Neurol 92:591\u2013600","journal-title":"Exp Neurol"},{"key":"818_CR4","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","volume":"10","author":"MA Cenci","year":"1998","unstructured":"Cenci MA, Lee CS, Bjorklund A (1998) l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694\u20132706","journal-title":"Eur J Neurosci"},{"key":"818_CR5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00002826-198403000-00005","volume":"7","author":"DR Cooper","year":"1984","unstructured":"Cooper DR, Marrel C, Testa B, van de Waterbeemd H, Quinn N, Jenner P, Marsden CD (1984) l-DOPA methyl ester\u2014a candidate for chronic systemic delivery of l-DOPA in Parkinson\u2019s disease. Clin Neuropharmacol 7:89\u201398","journal-title":"Clin Neuropharmacol"},{"key":"818_CR6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0014-2999(72)90149-5","volume":"20","author":"H Corrodi","year":"1972","unstructured":"Corrodi H, Farnebo LO, Fuxe K, Hamberger B, Ungerstedt U (1972) ET495 and brain catecholamine mechanisms: evidence for stimulation of dopamine receptors. Eur J Pharmacol 20:195\u2013204","journal-title":"Eur J Pharmacol"},{"key":"818_CR7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0014-2999(74)90111-3","volume":"28","author":"I Creese","year":"1974","unstructured":"Creese I (1974) Behavioural evidence of dopamine receptor stimulation by piribedil (ET495) and its metabolite S584. Eur J Pharmacol 28:55\u201358","journal-title":"Eur J Pharmacol"},{"key":"818_CR8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","volume":"179","author":"A Dekundy","year":"2007","unstructured":"Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179:76\u201389","journal-title":"Behav Brain Res"},{"key":"818_CR9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.brainres.2007.05.005","volume":"1158","author":"KB Dupre","year":"2007","unstructured":"Dupre KB, Eskow KL, Negron G, Bishop C (2007) The differential effects of 5-HT1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res 1158:135\u2013143","journal-title":"Brain Res"},{"key":"818_CR10","doi-asserted-by":"crossref","unstructured":"Fox SH, Henry B, Hill MP, Peggs D. Crossman AR, Brotchie JM (2001) Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan. Mov Disord 16:642\u2013650","DOI":"10.1002\/mds.1148"},{"key":"818_CR11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/BF01291788","volume":"103","author":"M Gerlach","year":"1996","unstructured":"Gerlach M, Riederer P (1996) Animal models of Parkinson\u2019s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987\u20131041","journal-title":"J Neural Transm"},{"key":"818_CR12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00210-004-0984-8","volume":"370","author":"M Gerlach","year":"2004","unstructured":"Gerlach M, van den Buuse M, Blaha C, Bremen D, Riederer P (2004) Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat. Naunyn Schmiedebergs Arch Pharmacol 370:388\u2013394","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"818_CR13","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00702-011-0728-0","volume":"118","author":"M Gerlach","year":"2011","unstructured":"Gerlach M, Riederer P, Scheller D (2011) Editorial. Mechanisms underlying and medical management of l-Dopa-associated motor complications. J Neural Transm 118:1659\u20131660","journal-title":"J Neural Transm"},{"key":"818_CR14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s002109900167","volume":"361","author":"R Grondin","year":"2000","unstructured":"Grondin R, Hadj Tahar A, Doan VD, Ladure P, Bedard PJ (2000) Noradrenoceptor antagonism with idazoxan improves l-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 361:181\u2013186","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"818_CR15","unstructured":"Halley P, Riederer P, van den Buuse M, Lohmueller K, Gerlach M (2010) Anti-dyskinetic effects of piribedil on levodopa-induced dyskinesia in the 6-hydroxydopamine-lesioned rat model of Parkinson\u2019s disease. Mov Disord 25 (Suppl S2):S209\u2013S209"},{"key":"818_CR16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/exnr.1998.6996","volume":"155","author":"B Henry","year":"1999","unstructured":"Henry B, Crossman AR, Brotchie JM (1999a) Effect of repeated l-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol 155:204\u2013220","journal-title":"Exp Neurol"},{"key":"818_CR17","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7","volume":"14","author":"B Henry","year":"1999","unstructured":"Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM (1999b) The \u03b12-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of l-dopa in the MPTP-lesioned primate model of Parkinson\u2019s disease. Mov Disord 14:744\u2013753","journal-title":"Mov Disord"},{"key":"818_CR18","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.lfs.2008.04.001","volume":"82","author":"G Herradon","year":"2008","unstructured":"Herradon G, Morales L, Gramage E, Alguacil LF (2008) Comparative study of alpha2-adrenoceptors in Fischer 344 and Lewis rats. Evidence for clonidine-induced place aversion. Life Sci 82:1186\u20131190","journal-title":"Life Sci"},{"key":"818_CR19","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00702-011-0698-2","volume":"118","author":"MM Iravani","year":"2011","unstructured":"Iravani MM, Jenner P (2011) Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm 118:1661\u20131690","journal-title":"J Neural Transm"},{"key":"818_CR20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbr.2010.04.034","volume":"213","author":"EL Lane","year":"2010","unstructured":"Lane EL, Dunnett SB (2010) Pre-treatment with dopamine agonists influence l-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat. Behav Brain Res 213:66\u201372","journal-title":"Behav Brain Res"},{"key":"818_CR21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","volume":"15","author":"M Lundblad","year":"2002","unstructured":"Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson\u2019s disease. Eur J Neurosci 15:120\u2013132","journal-title":"Eur J Neurosci"},{"key":"818_CR22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.nbd.2004.01.007","volume":"16","author":"M Lundblad","year":"2004","unstructured":"Lundblad M, Picconi B, Lindgren H, Cenci MA (2004) A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16:110\u2013123","journal-title":"Neurobiol Dis"},{"key":"818_CR23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pharmthera.2010.06.002","volume":"128","author":"MJ Millan","year":"2010","unstructured":"Millan MJ (2010) From the cell to the clinic: a comparative review of the partial D-2\/D-3 receptor agonist and alpha(2)-adrenoceptor antagonist, piribedil, in the treatment of Parkinson\u2019s disease. Pharmacol Therap 128:229\u2013273","journal-title":"Pharmacol Therap"},{"key":"818_CR24","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-3565(24)29611-7","volume":"297","author":"MJ Millan","year":"2001","unstructured":"Millan MJ, Cussac D, Milligan G, Carr C, Audinot V, Gobert A, Lejeune F, Rivet JM, Brocco M, Duqueyroix D, Nicolas JP, Boutin JA, Newman-Tancredi A (2001) Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human \u03b12-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther 297:876\u2013887","journal-title":"J Pharmacol Exp Ther"},{"key":"818_CR25","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/14656566.7.13.1715","volume":"7","author":"T M\u00fcller","year":"2006","unstructured":"M\u00fcller T, Russ H (2006) Levodopa, motor fluctuations and dyskinesia in Parkinson\u2019s disease. Exp Opin Pharmacother 7:1715\u20131730","journal-title":"Exp Opin Pharmacother"},{"key":"818_CR26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1124\/jpet.103.059519","volume":"309","author":"M Nakagawa","year":"2004","unstructured":"Nakagawa M, Ohgoh M, Nishizawa Y, Ogura H (2004) Dopaminergic agonists and muscarinic antagonists improve lateralization in hemiparkinsonian rats in a novel exploratory Y-maze. J Pharmacol Exp Ther 309:737\u2013744","journal-title":"J Pharmacol Exp Ther"},{"key":"818_CR27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/jpet.102.039875","volume":"303","author":"A Newman-Tancredi","year":"2002","unstructured":"Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and \u03b11\/\u03b12-adrenoceptor. J Pharmacol Exp Ther 303:805\u2013814","journal-title":"J Pharmacol Exp Ther"},{"key":"818_CR28","volume-title":"The rat brain in stereotaxic co-ordinates","author":"G Paxinos","year":"1986","unstructured":"Paxinos G, Watson C (1986) The rat brain in stereotaxic co-ordinates, 2nd edn. Academic Press, New York","edition":"2"},{"key":"818_CR29","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mds.1143","volume":"16","author":"O Rascol","year":"2001","unstructured":"Rascol O, Arnulf I, Peyro-Saint Paul H, Brefel-Courbon C, Vidailhet M, Thalamas C, Bonnet AM, Descombes S, Bejjani B, Fabre N, Montastruc JL, Agid Y (2001) Idazoxan, an alpha-2 antagonist, and l-DOPA-induced dyskinesias in patients with Parkinson\u2019s disease. Mov Disord 16:708\u2013713","journal-title":"Mov Disord"},{"key":"818_CR30","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/mds.21122","volume":"21","author":"O Rascol","year":"2006","unstructured":"Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A (2006) Early piribedil monotherapy of Parkinson\u2019s disease: a planned seven-month report of the REGAIN study. Mov Disord 21:2110\u20132115","journal-title":"Mov Disord"},{"key":"818_CR31","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/mds.10200","volume":"17","author":"LA Smith","year":"2002","unstructured":"Smith LA, Tel BC, Jackson MJ, Hansar MJ, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P (2002) Repeated administration of piribedil induces less dyskinesia than l-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord 17:887\u2013901","journal-title":"Mov Disord"},{"key":"818_CR32","doi-asserted-by":"crossref","unstructured":"Smith LA, Jackson MJ, Johnston L, Kuoppamaki M, Rose S, Al-Barghouthy G, Del Signore S, Jenner P (2006) Switching from levodopa to the long-acting dopamine D2\/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin Neuropharmacol 29:112\u2013125","DOI":"10.1097\/01.WNF.0000220818.71231.DF"},{"key":"818_CR33","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1124\/jpet.106.109207","volume":"319","author":"N Turle-Lorenzo","year":"2006","unstructured":"Turle-Lorenzo N, Maurin B, Puma C, Chezaubernard C, Morain P, Baunez C, Nieoullon A, Amalric M (2006) The dopamine agonist piribedil with l-DOPA improves attentional dysfunction: relevance for Parkinson\u2019s disease. J Pharmacol Exp Ther 319:914\u2013923","journal-title":"J Pharmacol Exp Ther"},{"key":"818_CR34","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0006-8993(70)90187-3","volume":"24","author":"U Ungerstedt","year":"1970","unstructured":"Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485\u2013493","journal-title":"Brain Res"},{"key":"818_CR35","unstructured":"Watling K (2006) The Sigma-RBI handbook of receptor classification and signal transduction. Sigma-RBI, Natick"},{"key":"818_CR36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","volume":"10","author":"C Winkler","year":"2002","unstructured":"Winkler C, Kirik D, Bjorklund A, Cenci MA (2002) l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson\u2019s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10:165\u2013186","journal-title":"Neurobiol Dis"},{"key":"818_CR37","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/mds.10359","volume":"18","author":"M Ziegler","year":"2003","unstructured":"Ziegler M, Castro-Caldas A, Del Signore S, Rascol O (2003) Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson\u2019s disease: a 6-month, randomized, placebo-controlled study. Mov Disord 18:418\u2013425","journal-title":"Mov Disord"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-012-0818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-012-0818-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-012-0818-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:54:01Z","timestamp":1743137641000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-012-0818-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,17]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["818"],"URL":"https:\/\/doi.org\/10.1007\/s00702-012-0818-7","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,17]]}}}